EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies

Hatice Terzi iD, Şeyma Taştemur, Ayşegül Öztürk, Neslihan Başgöz Karaguş, Mustafa Eymen Kontaş iD, Onur Mahmutoğlu, Ali Güngör iD, Mehmet Şencan

International Journal of Molecular Sciences · 22.05.2026 · 27 (11) · 4657

DOI: 10.3390/ijms27114657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.05.2026. Verfasst von Hatice Terzi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Department of Hematology, Faculty of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Türkiye. Hauptthemen laut MEDLINE: Apigenin, Proto-Oncogene Proteins c-akt, Signal Transduction, Antineoplastic Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematologic malignancies are driven by dysregulated growth and survival signaling pathways that promote proliferation, treatment resistance, and disease progression. Naturally derived compounds targeting multiple oncogenic pathways with low toxicity have gained interest. Apigenin, a dietary flavonoid, shows anticancer activity in solid tumors, but its molecular effects in hematologic malignancies remain unclear. The antineoplastic effects of apigenin were evaluated in K562 (chronic myeloid leukemia) and DOHH2 (B-cell lymphoma) cell lines. Cell viability was assessed using the CCK-8 assay. L929 (mouse fibroblast) cells were included to evaluate selectivity. EGFR, MAPK, PI3K, NF-κB, caspase-3, and caspase-7 levels were measured by ELISA. Apoptosis and cell cycle distribution were analyzed by flow cytometry. Apigenin reduced cell viability in a dose-dependent manner, with IC50 values of 84.14 μM (K562) and 70.11 μM (DOHH2). It suppressed EGFR, MAPK, PI3K, and NF-κB signaling and increased the caspase-3 and caspase-7 levels (p < 0.001). Flow cytometry showed S-phase arrest and increased apoptosis. L929 cells showed limited reduction in viability at higher concentrations. Apigenin exerts antiproliferative and pro-apoptotic effects via inhibition of the EGFR/MAPK and PI3K/Akt pathways and activation of caspase-mediated apoptosis. Lower sensitivity in L929 cells suggests relative selectivity, supporting further in vivo and clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApigeninProto-Oncogene Proteins c-aktSignal TransductionAntineoplastic AgentsHematologic NeoplasmsHumansPhosphatidylinositol 3-KinasesErbB ReceptorsAnimalsApoptosisMiceCell SurvivalCell Line, TumorNF-kappa BCell ProliferationK562 CellsMitogen-Activated Protein Kinases

Stichwörter der Autor:innen

DOHH2K562apigeninapoptosisgrowth signaling pathwayshematological malignancies

Substanzen

ApigeninProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesErbB ReceptorsAntineoplastic AgentsNF-kappa BMitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Internal Medicine, Department of Hematology, Faculty of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Türkiye.
  • Department of Internal Medicine, Faculty of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Türkiye.
  • Department of Therapy and Rehabilitation, Vocational School of Health Services, Sivas Cumhuriyet University, 58140 Sivas, Türkiye.
  • Department of Medical Genetics, Faculty of Medicine, Erciyes University, 38280 Kayseri, Türkiye.
  • Department of Family Medicine, Sivas Provincial Health Directorate, 58080 Sivas, Türkiye.
  • Laboratory and Veterinary Health Program, Health Services Vocational School, Osmaniye Korkut Ata University, 80000 Osmaniye, Türkiye.

ORCID-Profile: Hatice Terzi, Mustafa Eymen Kontaş, Ali Güngör

Zitieren

APA

Terzi, H., Taştemur, Ş., Öztürk, A., Başgöz Karaguş, N., Kontaş, M. E., Mahmutoğlu, O., Güngör, A., & Şencan, M. (2026). Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies. International Journal of Molecular Sciences, 27(11), 4657. https://doi.org/10.3390/ijms27114657

Vancouver

Terzi H, Taştemur Ş, Öztürk A, Başgöz Karaguş N, Kontaş ME, Mahmutoğlu O, et al. Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies. International Journal of Molecular Sciences. 2026;27(11):4657. doi:10.3390/ijms27114657

BibTeX
@article{Terzi2026,
  author = {Terzi, Hatice and Taştemur, Şeyma and Öztürk, Ayşegül and Başgöz Karaguş, Neslihan and Kontaş, Mustafa Eymen and Mahmutoğlu, Onur and Güngör, Ali and Şencan, Mehmet},
  title = {Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {4657},
  doi = {10.3390/ijms27114657}
}
Kostenlos starten →